About this trial
This study is looking at a new way to treat adults with recurrent or progressive oligodendroglioma, a type of brain cancer. The goal is to see how well a special treatment using the patient’s own immune cells works when combined with IDH1/2 inhibitors. Up to 12 patients will be included to check the safety and feasibility of this approach.
The trial's ID number is NCT06254326. This is a Phase 1 study, meaning it is one of the first steps to see how well the treatment works and how safe it is. The study aims to include about 12 participants and is regulated by the FDA.
Who can join
Adults aged 18 to 89 can participate. Both men and women are welcome. Participants must have a specific type of oligodendroglioma and must be candidates for surgery. The trial team will confirm if you meet the requirements.
Conditions
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive a new type of therapy. This includes up to 9 special vaccines made from their own immune cells, along with infusions of expanded immune cells and stem cells. Participants will also receive medication to help their immune system fight the cancer.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
University of Florida Health Shands Hospital
Gainesville, Florida